Are End-to-End CDMO Partnerships the Solution to Drug Development and Manufacturing Upheaval?

Industry trends

Optimizing drug development, manufacturing and supply is critical if pharmaceutical companies are to translate innovation into therapeutic and commercial gains that balance health benefits with affordable access and durable revenue streams. Yet the bar for achieving this kind of synergy, in an unpredictable operating environment, keeps getting higher.

Drug development costs continue to rise as deeper understanding of disease pathogenesis and pathways ramps up treatment specificity and complexity, all against a backdrop of more stringent drug regulation and payer scrutiny of product value. Even the lowest estimate for the average cost of bringing a new drug to market is $1.3 billion.